羟氯喹抑制紫外线诱导的系统性红斑狼疮CD4+T细胞白细胞介素-10和干扰素-γ的表达

目的 研究紫外线对系统性红斑狼疮(SLE)CD4+T细胞因子的影响和羟氯喹的抑制作用.方法 选择SLE 30例,健康对照10名.磁珠分选SLE患者和健康人的CD4+T细胞,紫外线311 nm窄谱中波紫外线暴露,加入羟氯喹共培养,酶联免疫吸附试验(ELISA)检测培养上清白细胞介素(IL)-10和干扰素-γ的表达水平.采用t检验进行统计学分析.结果 SLE患者CD4+T细胞IL-10表达高于健康对照[(27±4)和(18±3) pg/ml,P=0.011];经45、100 mJ/cm2紫外线暴露后,SLE活动患者CD4+T细胞IL-10表达升高[(27±4)和(77±42) pg/ml,(40±18)和(77±42) pg/ml,P=0.022,P=0.048],经100 mJ/cm2紫外线暴露后,活动患者CD4+T细胞IL-10表达高于稳定患者[(77±42)和(24±4)pg/ml,P=0.029];羟氯喹降低SLE活动患者CD4+T细胞IL-10和干扰素-γ表达[(2.6±4.0)和(17.9±2.3)pg/ml,P=0.018,P=-0.017)];羟氯喹降低经45,100 mJ/cm2紫外线暴露后SLE活动患者T细胞IL-10表达[(40±18)和(22±6)pg/ml,(77±42)和(21±5) pg/ml,P=0.037,P=0.04];羟氯喹降低经100 mJ/cm2紫外线暴露的SLE活动和稳定患者T细胞干扰素-γ表达[(18±3)和(13±14) pg/ml,(19±7)和(12±5) pg/ml,P=0.013,P=0.049].结论 紫外线加重SLE患者体内Th1/Th2细胞因子的比例失衡;羟氯喹抑制了紫外线诱发SLE患者干扰素-γ和IL-10的表达.

Abstract：

Objective To explore the role of hydroxychloroquine (HCQ) in ultraviolet B (UVB)- induced expression of interleukin (IL)-10 and interferon (IFN)-γ from CD4+T cells in patients with systemic lupus erythematosus (SLE). Methods Thirty patients with SLE and 10 healthy controls were enrolled in the study. CD4+ T cells were isolated using magnetic beads from SLE patients and healthy controls. HCQ was added in culture media before and after irradiation with UVB 311 nm narrow band ultraviolet B (NB-UVB). The levels of IL-10 and IFN-γ in the supernatant were detected with enzyme-linked immunosorbent (ELISA). Comparisons between groups were performed by t-test. Results The level of IL-10 was higher in SLE patients [(27±4) pg/ml] than that in healthy controls [(18±3) pg/ml, P=0.011]. After exposure of CD4+T cells to UVB in 45 or 100 mJ/cm2 dosages, the level of IL-10 was increased significantly in patients with active disease (P=0.022, P=0.048). After exposure of CD4+T cells to UVB in 100 mJ/cm2 dosages, the levels of IL-10 was higher in patients with active disease [(77±42) pg/ml] than patients with stable disease [(24± 4) pg/ml, P=0.029]. When CD4+ T cell were cultured with HCQ, IL-10 and IFN-γ levels in patients with active disease [(2.6±4.0), (17.5±2.3) pg/ml] were decreased significantly (P=0.018, P=0.017). HCQ reversed UVB-induced IL-10 expression in active SLE patients after exposure of CD4+T cells to UVB in 45 or 100 mJ/cm2 dosages (P=0.037, P=0.04). HCQ also reversed UVB-induced IFN-7 expression in active SLE patients and stable SLE patients after exposure to CD4+T cells with UVB in 100 mJ/cm2 dosages (P=0.013, P= 0.049). Conclusion UVB can aggravate the imbalance of Th1 and Th2 cytokines. HCQ inhibits UVB-induced IL-10 and IFN-7 expression of CD4+T cells in patients with SLE, especially in patients with active disease.     

延长聚乙二醇干扰素α-2a疗程对乙型肝炎表面抗原消失/血清学转换的影响

目的 探讨延长聚乙二醇干扰素α-2a疗程对慢性乙型肝炎患者获得HBsAg消失/血清学转换的影响.方法将217例慢性乙型肝炎患者根据体质量分为＜60 kg和≥60 kg两组,分别皮下注射聚乙二醇干扰素α-2a 135μg或180 μg,治疗过程中根据患者外周血中性粒细胞数和血小板数调整药物剂量.每3个月采用酶免疫化学发光法定量检测HBsAg/抗-HBs、HBeAg/抗-HBe,HBV DNA采用实时荧光定量聚合酶链式反应检测,将治疗时间＞12周的患者纳入统计分析,在治疗过程中,对HBV DNA、HBsAg含量降低的患者,HBeAg含量下降的HBeAg阳性患者,治疗48周后HBsAg含量＜200 IU/ml患者进行延长治疗,经意向性分析治疗患者HBsAg血清学转换发生率.采用x2检验进行统计学分析.结果 217例慢性乙型肝炎患者,治疗时间为12.0～197.6周,平均(53.1±33.4)周,其中118例患者治疗时间≥48周,89例治疗时间＜48周.13.4%(29/217)的患者获得HBsAg消失/HBsAg血清学转换,其治疗时间为17.6～197.6周,平均(75.4±42.8)周,其中治疗时间＞48周24例(82.8%),小于48周5例(17.2%);HBV DNA平均转阴时间为(20.8±8.9)周.148例HBeAg阳性患者中,9.5%(14/148)的患者获得HBsAg消失/血清学转换,在获得HBsAg消失/血清学转换的患者中,治疗时间均＞48周(54～194周),平均(81.3±39.4)周.21.7%(15/69)的HBeAg阴性患者获得HBsAg消失/血清学转换,与HBeAg阳性患者的HBsAg消失/血清学转换率(9.5%)比较,x2=6.129,P=0.013,差异有统计学意义.获得HBsAg消失/血清学转换的患者中,HBeAg阴性患者平均治疗时间为(70.2±48.0)周,HBeAg阳性患者(81.3±39.4)周,差异无统计学意义(t=-0.522,P=0.602).结论 对聚乙二醇干扰素α-2a治疗HBV DNA和HBsAg应答良好的慢性乙型肝炎患者,延长疗程可提高HBsAg消失/血清学转换率,HBeAg阴性患者比HBeAg阳性患者更容易通过延长聚乙二醇干扰素α-2a治疗获得HBsAg的消失/血清学转换.

Abstract：

Objective HBsAg loss and seroconversion in patients with chronic hepatitis B leads to long-lasting good clinical outcomes. The aim of this paper was to investigate to improve the rate of HBsAg loss and seroconversion in chronic hepatitis B patients by prolonged treatment of PEG-IFN α -2a. Methods 217 cases of HBeAg-positive or negative patients were collected from inpatient and outpatient in Beijing Ditan Hospital from May 2005 to October 2009 and subcutaeous injection of 135μg or 180μg PEGASYS were given once a week acording to body weights. The drug doses were adjusted acording to the neutrophilic granulocyte and platelet counts during treament course. Quantitative HBV DNA test was conducted using a commercially available real-time fluorescence quantitative PCR kit. The serum HBsAg/anti-HBs and HBeAg/anti-HBe were quantitatively detected by Abbott i 2000 chemiluminescent kit before and during treatment every three months. Patients with HBsAg steadily decreased and reached serum HBsAg level below 200 IU/ml after 48 weeks of treatment would receive prolonged treatment. Patients with more than 12 weeks of treatment entered into analysis. Main efficacy of prolonged treatment was evaluated by the incidences of HBsAg loss and seroconversion. Results The treatment courses of the 217 patients ranged from 12.0 to 197.6weeks with an average of 53.1±33.4 weeks, 118 cases took more than 48 weeks and another 89 cases less than 48 weeks. 13.4% (29/217) of patients achieved HBsAg loss or HBsAg seroconversion with treatment courses from 17.6 to 197.6 weeks (average 75.4±42.8 weeks). Among these 29 patients 24 (82.8%) received more than 48 weeks of treatment, but the treatment courses of HBV DNA reached undetectable level were 20.8±8.9 weeks. In this study, 9.5% (14/148) of HBeAg-positive patients acchieved HBsAg loss or seroconversion, all of them treated more than 48 weeks, from 48 to 194 weeks, average 81.32 ± 39.36 weeks.21.7% (15/69) of HBeAg-negative patients achieved HBsAg loss or seroconversion, significantly higher than that of HBeAg-positive patients (9.5%) (x2=6.129, P=0.013). The average treatment course for HBeAgnegative patients with HBsAg loss was 70.2±48.0 weeks, shorter than that of HBeAg-positive patients with HBsAg loss (81.3±39.4 weeks), but no significant difference (t=-0.522, P = 0.602) found between. Conclusion Higher rate of HBsAg loss and seroconversion could be obtained by individual extended treatment courses in patients with rapid HBV DNA and HBsAg response to PEG-IFN α -2a treatment and the HBeAgnegative patients could got higher rate of HBsAg loss than HBeAg-positive patients.     

慢性乙型肝炎患者树突状细胞功能与单个核细胞乙型肝炎病毒共价闭合环状DNA的关系

Objective To investigate the relationship between the maturity and function of dendritic cells (DC) and hepatitis B virus covalently closed circular DNA (HBV cccDNA) load in the peripheral blood mononuclear cells (PBMC)/monocyte-derived DC in patients with chronic hepatitis B (CHB). Methods The peripheral blood samples were collected from 29 patients with CHB and 10healthy controls. PBMC were isolated freshly and induced with granulocyte/macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). A large amount of DC were harvested after seven days of culture. The expressions of CD209, CD80, CD86, human leucocyte antigen (HLA)-DR and CD1a of DC were analyzed by flow cytometry. The HBV cccDNA load in PBMC and DC were measured by real-time polymerase chain reaction (PCR). The interleukin-12 (IL-12) level in the culture supernatant of DC was determined by enzyme linked immunosorbent assay (ELISA). The effects on T lymphocyte proliferation induced by DC were tested by mixed lymphocyte reaction (MLR). The data was compared by t test and analysis of variance. Results HBV cccDNA could be detected in PBMC from 16 patients, but not in DC from all 29 patients. HBV cccDNA load was all negatively correlated with the expressions of CD209 (r= -0. 793, P＜0.01), CD80 (r= -0. 581,P＜0.05), CD86 (r=-0. 698, P＜0.01), HLA-DR (r=-0. 817, P＜0.01), CD1a (r=-0. 734, P＜0.01), IL-12 level (r=-0. 632, P＜0.05) and allogenic T lymphocyte proliferation induced by DC (r=-0. 617, P＜0.05). The expressions of CD209, CD80, CD86, CD1a and HLA-DR on DC,IL-12 level in culture supernatant of DC and the allogenic T lymphocyte proliferation induced by DC in patients with positive PBMC HBV cccDNA were all significantly lower compared to those in healthy controls, and the changes of the parameters mentioned above were greater in PBMC HBV cccDNA positive patients than those in PBMC HBV cccDNA negative patients (P ＜ 0. 05 or P ＜ 0. 01).Conclusions The function and maturity of DC are impaired in CHB patients. HBV cccDNA can be detected in PBMC from CHB patients. Moreover, the higher PBMC HBV cccDNA is, the worse DC function and maturity are, which could be one of the important mechanisms of HBV persistent infection.     

慢性乙型肝炎患者树突状细胞功能与单个核细胞乙型肝炎病毒共价闭合环状DNA的关系

Objective To investigate the relationship between the maturity and function of dendritic cells (DC) and hepatitis B virus covalently closed circular DNA (HBV cccDNA) load in the peripheral blood mononuclear cells (PBMC)/monocyte-derived DC in patients with chronic hepatitis B (CHB). Methods The peripheral blood samples were collected from 29 patients with CHB and 10healthy controls. PBMC were isolated freshly and induced with granulocyte/macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). A large amount of DC were harvested after seven days of culture. The expressions of CD209, CD80, CD86, human leucocyte antigen (HLA)-DR and CD1a of DC were analyzed by flow cytometry. The HBV cccDNA load in PBMC and DC were measured by real-time polymerase chain reaction (PCR). The interleukin-12 (IL-12) level in the culture supernatant of DC was determined by enzyme linked immunosorbent assay (ELISA). The effects on T lymphocyte proliferation induced by DC were tested by mixed lymphocyte reaction (MLR). The data was compared by t test and analysis of variance. Results HBV cccDNA could be detected in PBMC from 16 patients, but not in DC from all 29 patients. HBV cccDNA load was all negatively correlated with the expressions of CD209 (r= -0. 793, P＜0.01), CD80 (r= -0. 581,P＜0.05), CD86 (r=-0. 698, P＜0.01), HLA-DR (r=-0. 817, P＜0.01), CD1a (r=-0. 734, P＜0.01), IL-12 level (r=-0. 632, P＜0.05) and allogenic T lymphocyte proliferation induced by DC (r=-0. 617, P＜0.05). The expressions of CD209, CD80, CD86, CD1a and HLA-DR on DC,IL-12 level in culture supernatant of DC and the allogenic T lymphocyte proliferation induced by DC in patients with positive PBMC HBV cccDNA were all significantly lower compared to those in healthy controls, and the changes of the parameters mentioned above were greater in PBMC HBV cccDNA positive patients than those in PBMC HBV cccDNA negative patients (P ＜ 0. 05 or P ＜ 0. 01).Conclusions The function and maturity of DC are impaired in CHB patients. HBV cccDNA can be detected in PBMC from CHB patients. Moreover, the higher PBMC HBV cccDNA is, the worse DC function and maturity are, which could be one of the important mechanisms of HBV persistent infection.     

恩替卡韦治疗后慢性乙型肝炎患者外周血T淋巴细胞表面程序性死亡受体1表达与HBeAg血清学转换的关系

目的 动态观察慢性乙型肝炎患者恩替卡韦抗病毒治疗后不同时期外周血T淋巴细胞(简称T细胞)表面程序性死亡受体1(PD-1)表达的变化,并探讨其与HBeAg血清学转换间的关系.方法 对20例HBeAg阳性慢性乙型肝炎患者予以恩替卡韦抗病毒治疗并随访51周,根据HBeAg是否发生血清学转换分为:HBeAg未转换组(14例),HBeAg转换组(6例).分别于治疗前(基线,T0)、治疗2～4周(T1)、治疗5～10周(T2)、治疗11～20周(T3)、治疗21～30周(T4)、治疗31～51周(T5)收集外周血,流式细胞术检测CD4+、CD8+T细胞表面PD-1的表达水平,实时荧光定量PCR检测血清HBV DNA载量,同时检测血清ALT水平.正态分布资料采用独立样本t检验,非正态分布者采用Mann-Whitney U检验比较组间差异,相关性分析采用Pearson相关分析.结果 治疗前两组患者血清HBV DNA载量分别为(7.54±0.67)log10拷贝/ml、(7.30±0.79)log10拷贝/ml(P＞0.05),ALT水平为(187.26±184.15)U/L、(272.17±215.07)U/L(P＞0.05),外周血CD4+T细胞表面PD-1表达水平为6.04%±3.71%6.77%±2.88%(P＞0.05),CD8+T细胞表面PD-1表达水平为6.39%±3.33%、8.88%±2.84%(P＞0.05).恩替卡韦抗病毒治疗后两组患者血清HBV DNA载量、ALT水平的下降与CD4+、CD8+T细胞表面PD-1表达的下调呈显著正相关(r=0.212,P=0.05;r=0.377,P＜0.01;r=0.279,P＜0.05;r=0.347,P＜0.01).在相同的随访时间段内,HBeAg转换组血清HBV DNA载量、ALT水平及外周血CD4+、CD8+T细胞表面PD-1表达的下降率均高于HBeAg未转换组,且两组间△ T0～T1、△T0～T2期HBV DNA的下降率及△T0～T2、△T0～T3期CD8+T细胞表面PD-1表达的下降率差异有统计学意义(分别为49.9%对比37.3%,56.7%对比47.4%,70.1%对比-4.2%,66.9%对比24.5%,P值均＜0.05).结论 HBeAg阳性慢性乙型肝炎患者经恩替卡韦抗病毒治疗后,外周血CD8+T细胞表面PD-1表达的快速下调与血清HBV DNA相似,可作为预测后期HBeAg血清学转换的指标之一.

Abstract：

Objective To observe longitudinally the expression of Programmed death 1 (PD-1) on peripheral blood T cells in chronic hepatitis B patients underwent antiviral treatment with entecavir (ETV)and to explore the relationship between PD-1 expression and HBeAg seroconversion.Methods Twenty HBeAg positive patients underwent antiviral treatment with ETV were followed up for 51 weels.14 patients remained HBeAg positive and 6 patients achieved HBeAg seroconversion.Peripheral blood was collected at six time points:T0:baseline,T1:2-4week;T2:5-10week;T3:11-20week;T4:21-30week:T5:31-51week.PD-1 expressions on T cells were assessed by flow cytometry.Serum HBV DNA loads were determined by real-time fluorescent quanttative polymerase chain reaction (PCR) and serum ALT levels were examined at the same time.Results At baseline,serum HBV DNA load of patients without HBeAg seroconversion and with HBeAg seroconversion were (7.54 ± 0.67) log10 copies/ml and (7.30 ± 0.79) log10 copies/ml(P ＞ 0.05),the ALT levels were (187.26 ± 184.15) U/L and (272.17 ± 215.07) U/L (P ＞ 0.05),PD-1 exprissions on CD4+ T cells were 6.04% ± 3.71% and 6.77% ± 2.88% (P ＞ 0.05),PD-1 exprissions on CD8+ T cells were 6.39% ± 3.33% and 8.88% ± 2.84% (P ＞ 0.05).After ETV treatment,serum HBV DNA loads and ALT levels both decreased gradually,which was positively correlated with PD-1 expressions on CD4+ and CD8+ T cells (r = 0.212,P = 0.05;r = 0.377,P ＜ 0.01;r = 0.279,P ＜ 0.05;r = 0.347,P ＜ 0.01 ).During the same monitoring period,the HBV DNA loads,ALT levels and PD-1 expressions on T cells of the patients with HBeAg seroconversion decreased significantly as compared with the patients without HBeAg seroconversion.Besides,the decrease of HBV DNA loads during period △ T0-T1 and △ T0-T2 and PD-1 expressions on CD8+ T cells during period △ T0-T2 and △ T0-T3 were significantly different between these two kinds of patients (49.9% vs 37.3%,P ＜ 0.05;56.7% vs 47.4%,P ＜ 0.05;70.1% vs -4.2%,P ＜ 0.05;66.9% vs 24.5%,P ＜ 0.05).Conclusion The rapid decrease of PD-1 expression on peripheral CD8+ T cells after antiviral treatment with ETV is positvely correlated with the decrease of serum HBV DNA loads and may be used as a predictive index for HBeAg seroconversion in HBeAg positive patients.     

长片段RNA抑制HepG2.2.15细胞中HBV基因的表达和复制

目的 评估长的反义RNA干扰片段在培养细胞株中对HBV复制的抑制效应.方法将HBV基因组S区的全部核苷酸序列插入至pTARGETTM载体中,并将重组载体转染入HepG2.2.15细胞中.用酶联免疫吸附法检测HBsAg与HBeAg水平,用荧光定量PCR法检测HBVDNA水平.对数据采用多个独立样本Kruskal-Wallis检验与两两比较的Mann-Whitney U检验.结果 经过处理后,HepG2.2.15细胞上清液中HBsAg表达量(A值)在HBS2组(携带长片段反义RNA)为0.621±0.027,在HBS4组(携带正义RNA)为3.399±0.018,对照组为2.232±0.187;HBeAg表达量(A值)在HBS2组、HBS4组和对照组分别为0.749±0.019、1.548±0.025和1.570±0.044; HBV DNA水平(×104拷贝/ml)在HBS2组、HBS4组、对照组分别为1.597±0.082、3.381±0.297和3.610±0.063.与对照组相比,HBS2组HBsAg、HBeAg和HBV DNA表达量均降低,统计量Z值均为-2.309,P值均＜0.05; HBS4组HBsAg表达量增高(Z=-2.309,P＜0.05),而HBeAg和HBV DNA表达量无明显差异,统计量Z值分别为-0.866、-1.155,P值均＞0.05.结论 长片段反义RNA能抑制HBV基因的表达和病毒复制.

Abstract：

Objective To evaluate the inhibitory effects of long antisense RNA on HBV replication in HepG2.2.15 cells. Methods The coding region of HBV S gene was cloned into pTARGET vector in sense and antisense orientations and the recombinant plasmids were transfected into HepG2.2.15 cells which were divided into HBS2 (antisense RNA) group, HBS4 (sense RNA) group and control group. HBsAg and HBeAg in the culture supernant were detected by ELISA. The HBV DNA in the supernant was quantified by real-time PCR. Results After treatment, the levels of HBsAg in HepG2.2.15 cell supernatants of three groups were 0.621 ± 0.027, 3.399 ± 0.018 and 2.232 ± 0.187 respectively; the levels of HBeAg were 0.749 ± 0.019,1.548 ± 0.025 and 1.570 ± 0.044 respectively and the levels of HBV DNA were 1.597 ± 0.082, 3.381 ± 0.297 and 3.610 ± 0.063 respectively. The expressions of HBsAg and HBeAg and the HBV DNA level in HBS2 group were remarkably reduced as compared to the control (Z = -2.309, P ＜ 0.05); whereas the sense plasmid transfection (HBS4) did not affect HBeAg (Z= -0.866) and HBV DNA (Z = -1.155) levels in the culture supernant but slightly increased the HBsAg level (Z = -2.309). Conclusion Antisense RNA might be a useful tool to repress HBV replication.     

慢性乙型肝炎患者抗病毒治疗过程中程序性死亡分子1及其配体表达的变化

目的 探讨慢性乙型肝炎患者在抗病毒治疗过程中程序性死亡分子1(PD-1)及其主要配体PD-L1表达的变化情况及其与HBeAg/抗-Hbe血清学转换的关系.方法 对10例人类白细胞抗原(HLA)-A2阳性的HBeAg阳性慢性乙型肝炎患者予以替比夫定抗病毒治疗24 周,分别于治疗的0、12周和24周随访,检测HBV DNA水平、外周血单个核细胞(PBMC)表面PD-1和PD-L1表达水平、HBV特异性T淋巴细胞数量与其表达PD 1水平,及PBMC体外培养上清液中干扰素(IFN)γ水平.其中HBV DNA定量采用荧光定量PCR法检测;PBMC自新鲜血分离,部分PBMC加入重组HBcAg体外培养7d,加入HBV抗原表位肽五聚体复合体;PD-1和PD-L1阳性细胞、CD8'T淋巴细胞以及CD8和PD-1双阳性细胞用流式细胞仪检测;IFN γ水平用酶联免疫吸附试验检测.比较不同时间点PBMC表面PD-1和PD L1表达水平、HBV特异性CD8'T淋巴细胞数量及其PD-1表达水平、PBMC培养上清液中IFN γ水平.对抗病毒治疗前后对应指标数值的变化采用配对t检验分析.结果 治疗前HBV DNA水平为5.16～8.77 log10拷贝/ml,治疗24周时,7例HBV DNA水平低于检测下限,3例仍可检测到,但明显低于基线水平.2例HBeAg/抗-Hbe血清学转换,2例HBeAg阴转,6例仍维持HBeAg阳性.0、12周和24周PBMC表面PD 1表达水平分别为52.1%±17.0%、39.1%±18.2%和23.4%±16.3%(24周和0周比较,P＜0.01);PD-L1分别为45.6%±15.4%、34.6%±16.2%和20.9%±9.5%(24周和0周,P＜0.01;24周和12周比较P＜0.05);HBV特异性T淋巴细胞上PD-1表达水平分别为76.2%±10.4%、66.5%±15.4%和49.5%±25.3%(24周和0周比较,P＜0.01;12周和0周比较,P＜0.05;24周和12周比较,P＜0.05);HBV特异性T淋巴细胞分别为1.3%±0.5%、1.5%±1.0%和2.2%±1.5%; IFN γ水平(pg/ml)分别为91.7±82.1、99.4+93.5和109.0+86.6.24周HBeAg/抗-Hbe血清学转换者上述指标变化明显大于无HBeAg/抗-Hbe血清学转换者.结论 直接抑制HBV复制能降低PD-1、PD-L1表达水平,并增加HBV特异性CD8'T淋巴细胞的数量和功能.早期PD-1快速下降和HBV特异性T淋巴细胞数量及功能的恢复与早期HBeAg/抗-Hbe血清学转换的关系有待于进一步研究.     

调节性T淋巴细胞对成人乙型肝炎疫苗接种免疫应答的影响

目的 通过对乙型肝炎疫苗接种后不同免疫应答人群调节性T淋巴细胞(Treg细胞)Foxp3 mRNA的表达和细胞因子分泌的检测,探讨乙型肝炎疫苗接种后免疫应答与免疫调节细胞和细胞因子之间的内在联系.方法 采集不同反应人群全血,实时荧光定量PCR检测人外周血单个核细胞Foxp3 mRNA的表达;流式细胞术对外周血单核细胞的表面标志物CD4、CD25进行检测;酶联免疫法检测外周血单个核细胞植物血凝素(PHA)和HBsAg刺激后白细胞介素(IL)-4、IL-12、IL-18、干扰素(IFN)γ的产生水平.根据不同资料采用方差分析、q检验或相关分析进行统计学处理.结果 (1)PHA和HBsAg刺激前后,无应答组Foxp3的表达均高于应答组和对照组,差异有统计学意义(P＜0.05).(2)应答组外周血CD4+CD25+Treg细胞占CD4+T淋巴细胞的百分比(0.59%±0.46%)明显低于对照组(1.30%±1.44%),差异有统计学意义(F=2.990,P＜0.01).(3)各组外周血单个核细胞经PHA和HBsAg刺激后,无应答组的IFN γ浓度[(11.00±9.03)U/ml]明显低于应答组[(38.88±28.16)U/ml],差异有统计学意义(P＜0.01).(4)各组外周血单个核细胞经PHA和HBsAg刺激后,IL-18、IL-4、IL-12的浓度差异均无统计学意义.结论 CD4+CD25+Foxp3+Treg细胞在一定程度上参与了乙型肝炎疫苗接种应答的负性调控;乙型肝炎疫苗接种后无应答与IFN γ分泌不足有关;抗-HBs滴度水平与IFN γ和CD4+CD25+Foxp3表达无相关性.     

脂多糖对人外周血树突状细胞成熟的影响

目的 通过研究内毒素的不同作用方式,模拟慢性乙型肝炎肠源性内毒素血症,探讨脂多糖(LPS)对人外周血树突状细胞(DC)成熟的影响.方法 用重组人粒细胞集落刺激因子、重组人白细胞介素-4、酪氨酸激酶受体3配体和肿瘤坏死因子α体外诱导、培养人外周血单个核细胞.分为持续刺激组:于1、4、7、9 d加入LPS 1 μg/ml;短期刺激组:于7、8 d加入LPS 1 μg/ml;对照组:不加LPS.观察细胞形态,用流式细胞仪检测细胞表型,混合淋巴细胞反应检测DC刺激T淋巴细胞的能力,用酶联免疫吸附法检测DC分泌细胞因子的水平.组间比较采用SPSS10.0统计学软件进行单因素方差分析,进一步两两比较用SNK法.结果 DC表达人白细胞-DR抗原、CD86、CD80、CD83分子水平,持续刺激组分别为65.81%±10.96%、48.81%±18.13%、13.56%±5.48%、11.52%±5.09%,对照组分别为78.43%±20.34%、51.29%±15.75%、15.22%±5.53%、15.64%±5.26%,短期刺激组分别为89.83%±16.99%、69.90%±24.05%、25.97%±10.81%、25.96%±10.59%,持续刺激组DC表面分子表达水平低于短期刺激组和对照组,各组比较,F值分别为3.376、3.823、4.535、5.320,P值均＜0.05,差异均有统计学意义.3组DC诱导同种异体混合T淋巴细胞的增殖指数分别为1.593±0.303、1.949±0.240、1.548±0.365,各组比较,F=3.572,P=0.049,差异有统计学意义.3组DC表达干扰素γ水平短期刺激组为(40.52±11.38)pg/ml,高于对照组和持续刺激组[分别为(21.57±7.68)pg/ml、(15.6±5.83)pg/ml],各组比较,F=3.403,P=0.019,差异有统计学意义.3组DC表达白细胞介素12水平短期刺激组为(84.45±31.28)pg/ml,高于对照组和持续刺激组[分别为(54.42±20.34)pg/ml、(51.77±11.02)pg/ml],各组比较,F=2.212,P=0.088,差异有统计学意义.结论 LPS持续刺激可抑制DC的发育成熟,可能是肠源性内毒素血症患者细胞免疫功能低下的原因所在.     

不同浓度甲氨蝶呤对外周血单个核细胞表达和分泌白细胞介素-17的影响

目的 体外观察不同浓度的甲氨蝶呤(MTX)对外周血单个核细胞(PBMCs)表达和分泌白细胞介素(IL)-17的影响,探究MTX有效治疗类风湿关节炎(RA)的可能机制.方法 分离RA患者和健康人PBMCs,予不同浓度MTX预处理,抗人CD3和抗人CD28刺激后,37 ℃体积分数为0.05的CO2培养箱培养.分别于培养的不同阶段收集细胞或上清液,采用反转录聚合酶链反应(RT-PCR)技术分析IL-17mRNA的表达水平;酶联免疫吸附试验(ELISA)法检测细胞培养液中IL-17的浓度;荧光抗体标记细胞表面抗原CD4和胞内蛋白 IL-17,流式细胞仪分析CD4+IL-17+细胞的比例.结果 比较采用两两配对t检验或独立样本t检验.结果 浓度为0.1、1.0、5.0、25.0μg/ml MTX组IL-17mRNA/GAPDH比值分别为(0.58±0.09、0.48±0.11、0.50±0.09、0.51±0.14),与无药抗体组(0.76±0.08)组间两两比较差异有统计学意义(P＜0.01);IL-17分泌水平则分别为(121±54)、(104±45)、(90±36)、(115±41)pg/ml,与无药抗体组(370±187)pg/ml组间两两比较差异有统计学意义(P＜0.01);MTX处理组CD4+IL-17+细胞比例的平均值下降,但统计学检验差异无统计学意义(P＜0.05).结论 MTX可以有效抑制PBMCs合成和分泌IL-17,而且在一定的剂量下可发挥显著作用,加大剂量并不能增强该作用.     

乙型肝炎病毒转基因小鼠免疫耐受状态及血液生物化学指标的研究

目的 了解HBV转基因鼠HBV基因的复制表达和免疫耐受状态,为探讨乙型肝炎发病机制和抗HBV新药评价提供可靠的参考依据.方法 选取遗传背景相同的SPE级HBsAg阴性非转基因鼠和转基因鼠.化学发光法检测HBsAg、HBeAg、HBV DNA,ELISA检测前S1、HBcAg,肝组织行病理学检查,免疫组织化学染色检测不同时期转基因鼠肝HBsAg表达,流式细胞仪检测小鼠淋巴细胞增殖情况,酶联免疫斑点检测(ELISPOT)分泌IFNγ的T淋巴细胞斑点数,双色免疫荧光法检测脾细胞悬液和脾树突状细胞(DC)中Toll样受体(TLR)2和TLR9的表达.数据行t检验和F检验.结果 HBV转基因鼠可复制表达HBsAg、前S1、HBeAg、HBcAg和HBVDNA,而抗-HBs、抗-HBc、抗-HBe均阴性;肝组织无明显病理改变,肝细胞中HBsAg在胞质表达,HBcAg在胞核表达.HBsAg刺激后,HBV转基因鼠T淋巴细胞增殖能力为(697.6±67.3)cpm,显著低于非转基因鼠的(1315.5±191.6)cpm.经HBsAg刺激后,HBV转基因鼠脾细胞分泌IFNγ的T淋巴细胞斑点数为8.25±1.10,低于非转基因鼠的28.50±4.21(F=155.967,P=0.000).HBV转基因DC表达CD11c+、TLR2和TLR9与非转基因鼠比较,差异无统计学意义(均P＞0.05).在18日龄胎鼠和1日龄仔鼠肝组织观察到HBsAg表达.结论 HBV转基因鼠有HBV相关抗原表达,并对HBV相关抗原存在免疫耐受,其先天和获得性免疫功能均正常,类似于人类慢性HBV无症状携带者.HBV转基因鼠是比较理想的动物模型.     

The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response

BACKGROUND/AIMS: The aim of this study was to examine the influence of the viral load on costimulatory effects of rhIL-12 on the hepatitis B virus (HBV)-induced immune response. METHODS: Peripheral blood mononuclear cells of HBsAg positive patients without cirrhosis were stimulated with HBsAg, HBcAg, preS1Ag and tetanus toxoid in the absence or presence of IL-12 (0.01, 0.1 and 1 ng/ml). Stimulation by alpha-CD3+alpha-CD28, pokeweed mitogen (PWM) and lipopolysaccharide (LPS) were used as controls. Then, proliferation and cytokine production were determined by 3H-thymidine uptake and ELISA after 72 h. The patients were divided into group 1 (n=21): HBV-DNA: not detectable, group 2 (n=13): HBV-DNA: <300 pg/ml, and group 3 (n= 10): HBV-DNA: >300 pg/ml. RESULTS: After stimulation with only HBV antigens, the highest amounts of IL-10 were found in group 3, while interferon (IFN)-gamma was rarely detectable. After stimulation with IL-12 and HBV antigens, strong costimulatory effects on IFN-gamma production, as well as proliferation, were observed in all patients except individuals from group 3. With regard to antigen-unrelated stimulation, significantly lower amounts of LPS-induced IFN-gamma production and alpha-CD3+28 induced proliferative responses, but higher amounts of LPS-induced IL-10 were observed in group 3. CONCLUSIONS: These data suggest that the presence of high amounts of HBV-DNA in serum is associated with suppressed co-stimulatory and regulatory effects of IL-12 on the immune response to HBV antigens. This may be one explanation for the poor response to immunostimulating therapy in patients with a high viral load.     

Toll-like Receptor and Hepatitis B Virus Clearance in Chronic Infected Patients: A Long-Term Prospective Cohort Study in Taiwan

Background.We sought to elucidate the impacts of the Toll-like receptors (TLRs) on spontaneous hepatitis B virus (HBV) e antigen (HBeAg) and hepatitis B s antigen (HBsAg) seroconversion in chronic HBV-infected patients. Methods.Human TLR2, TLR4, TLR5, and TLR9 gene polymorphisms were assessed in 278 HBeAg-positive, chronic HBV-infected patients. Additionally, HBV core antigen (HBcAg) in vitro stimulation using peripheral blood mononuclear cells (PBMCs) from 113 patients was done to assess interferon γ (IFN- γ) production. Results.Of the study subjects, 204 (73.4%) developed spontaneous HBeAg seroconversion, 21 (7.6%) developed spontaneous HBsAg clearance, and 10 (3.6%) had spontaneous HBsAg seroconversion during the 19.1?±?9.9 years of follow-up. The T allele at TLR5 rs5744174 (p.Phe616Leu) and the C allele at TLR9 rs5743836 promoter predicted earlier HBeAg seroconversion (hazard ratios [HRs], 2.45 and 3.65; P?=?.04, and .006, respectively). The TLR5 rs5744174 T allele carriers have higher PBMCs IFN-γ secretion to HBcAg stimulation (P=?.0002). The G allele carriers at TLR4 rs4986790 (p.Asp299Gly) predicted spontaneous HBsAg seroclearance (HR, 18.73; P?相似文献   

霉菌性阴道炎患者体内真菌分布、T淋巴细胞及相关细胞因子水平变化特点及意义

目的探讨霉菌性阴道炎患者体内真菌分布、T淋巴细胞及炎性细胞因子水平变化特点及意义。方法选取2017年1月—12月在我院治疗的霉菌性阴道炎患者182例作为观察组,同时选取女性健康志愿者110例作为对照组,检测2组受试者阴道分泌物中T淋巴细胞及细胞因子水平,同时对观察组阴道分泌物进行真菌培养。结果 182例患者中,病原菌以白色念珠菌为主,占43.41%;观察组阴道分泌物CD3~+、CD4~+和CD8~+T淋巴细胞水平分别为(52.12±10.45)%、(33.30±8.23)%和(25.10±9.22)%,明显低于对照组(P均0.05);观察组阴道分泌物IL-2、TNF-α和IFN-γ分别为(7.21±1.42)pg/ml、(17.90±4.55)pg/ml和(19.81±4.50)pg/ml,明显低于对照组(P均0.05),而IL-4和IL-10分别为(40.32±8.33)pg/ml和(25.66±4.33)pg/ml,明显高于对照组(P均0.05);复杂性霉菌性阴道炎患者阴道分泌物CD3~+、CD4~+、CD8~+T淋巴细胞以及IL-2、TNF-α和INF-γ水平明显低于普通霉菌性阴道炎患者(P均0.05),而IL-4和IL-10明显高于普通霉菌性阴道炎患者(P均0.05)。结论霉菌性阴道炎病原体以白色念珠菌为主,Th1/Th2细胞介导的细胞免疫参与了疾病过程。     

p38 mitogen‐activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg‐negative chronic hepatitis B

The mitogen‐activated protein kinase p38 (MAPK) is implicated in the induction of immune responses by regulating the differentiation of T lymphocytes and production of cytokines. Our aim was to investigate p38MAPK phosphorylation in different stages of the natural history of hepatitis B virus (HBV) infection. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll‐Hypaque density‐based centrifugation from 10 patients with HBeAg‐negative chronic hepatitis B [HBeAg(?) CHB;HBV‐DNA>2000IU/mL], eight patients with HBeAg‐negative chronic HBV infection [HBeAg(?) CI;undetectable HBV‐DNA] and 8 healthy controls (HCs). p38MAPK phosphorylation was assessed by phospho‐specific flow cytometry in PBMCs and cell subsets (CD3+,CD3?,CD56+,CD56?) after stimulation with cytokines (IL‐12+IL‐2 and IL‐12+IL‐18) or nonspecific stimuli [arsenite, phorbol 12‐myristate 13‐acetate (PMA) and ionomycin] at 0,30,60,120 and 240 minutes using p38 phospho‐specific conjugated antibodies. ΙFN‐γ was determined by ELISA in PBMCs culture supernatants after stimulation with rhIL‐2, rhIL‐12 and rhIL‐18, with and without pre‐treatment with the p38 MAPK inhibitor, SB203580. HBeAg(?) CI patients showed the highest expression of phosphor‐p38 MAPK in total PBMCs and subpopulations compared to HBeAg(?) CHB and HCs. A striking impairment in p38 phosphorylation was noted in CD56+ cells and in especially in NK cells (CD3‐CD56+). SB203580‐induced inhibition of p38MAPK phosphorylation was associated with suppression of IFN‐γ production in all groups. The universal lack of p38 MAPK activation in CD56+ and in particular in NK cells from HBeAg(?) CHB patients during viremia suggests a potential cell‐dependent implication of this pathway in the natural history of HBV infection.